Press Releases Items Per Page 102550 News Category FinancialGeneral Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 NKTR-102 Receives Positive Opinion From EMA COMP for Orphan Medicinal Product Designation in Ovarian Cancer Jul 18, 2011 Data from Phase 1 Study of NKTR-181 Demonstrate Proof-of-Concept for Nektar's Novel Opioid Analgesic Candidate Jun 07, 2011 NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® Jun 05, 2011 NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting Jun 04, 2011 Nektar Therapeutics' President and CEO Howard W. Robin to Present at the Jefferies 2011 Global Healthcare Conference in New York Jun 01, 2011 Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting May 18, 2011 Nektar Therapeutics Reports First Quarter 2011 Financial Results Apr 27, 2011 FDA Grants Orphan Drug Designation for Nektar's Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer Apr 21, 2011 Nektar to Announce Financial Results for the First Quarter of 2011 on Wednesday, April 27, 2011, After Close of U.S.-Based Financial Markets Apr 18, 2011 Nektar Initiates Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Pain Mar 21, 2011 Pagination First page « first Previous page ‹ previous … Page 34 Page 35 Page 36 Page 37 Current page 38 Page 39 Page 40 Page 41 Page 42 … Next page next › Last page last »